RxDoctor Payments Data

Morgan Davis

Physician Assistant · Wilmington, NCNPI 1871951145

Payments from drug & device makers

$3,895in general payments, 2019–2025

Across 131 payments — averaging $29.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Medtronic$689
  • Pfizer$420
  • Johnson & Johnson$303
  • Urogen Pharma, Inc.$281
  • Endo Pharmaceuticals Inc.$199
  • plus $955 from 22 others

What the payments were for

  • Food & beverage$3,62293%
  • Education$2737%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,895 in reported general payments places this provider in the 90th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$35,385
Medicare patients
295
Services billed
14,726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide11$162,698
GemtesaVibegron86$77,680
MyrbetriqMirabegron29$22,215
Tamsulosin Hcl470$8,766
Testosterone Cypionate145$5,476
Potassium Citrate ErPotassium Citrate35$3,984
Oxybutynin Chloride ErOxybutynin Chloride173$3,588
Testosterone20$3,314
Solifenacin Succinate91$3,040
Silodosin24$1,830
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst96$1,715
Estradiol28$1,436
Finasteride108$1,315
Dutasteride39$1,208
Cefdinir27$464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,049$184,91340 claims
Sumitomo Pharma America, Inc.Gemtesa$170$77,68086 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →